Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a micro-cap pharmaceutical company with a market capitalization of $3.12 million, has amended its agreement with contract research organization ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

"What is a tumor?" This is the fundamental question to answer if we want to treat cancer effectively. Our vision of cancer ...

Children, teens and young adults have a higher risk of dying from cancer if they were raised in a neighborhood that ...

Aging cells secrete substances known to promote the growth of cancer cells. The development of drugs that can selectively kill these cells or inhibit the secretion of substances is ongoing.

Researchers have identified two microRNA that may predict which individuals with cancer are at elevated risk for ...

A team led by the Cancer Immunogenomics group at the Josep Carreras Leukaemia Research Institute, the Computational Biology group at the Barcelona Supercomputing Center and the Germans Trias i Pujol ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

The field of cancer treatment is witnessing rapid advancements due to progress in proteomics, genomics, and drug discovery. These technologies have ...

Baseline histologic activity predicted colectomy risk in ulcerative colitis treated with biologics, independent of clinical or endoscopic factors.

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.